OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications	292
Alzheimer’s disease: targeting the peripheral circulation	190
Tau interactome and RNA binding proteins in neurodegenerative diseases	188
A partial Drp1 knockout improves autophagy flux independent of mitochondrial function	172
Immune cell metabolic dysfunction in Parkinson’s disease	171
Loss of MEF2C function by enhancer mutation leads to neuronal mitochondria dysfunction and motor deficits in mice	167
Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	167
Regulation of the hippocampal translatome by Apoer2-ICD release	156
Regulation of cortical hyperexcitability in amyotrophic lateral sclerosis: focusing on glial mechanisms	141
Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease	139
Challenge accepted: uncovering the role of rare genetic variants in Alzheimer’s disease	139
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	136
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	131
Positron emission tomography tracers for synucleinopathies	130
Aging-associated sensory decline and Alzheimer’s disease	128
Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come	125
Correction to: Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	125
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma	113
AIF3 splicing switch triggers neurodegeneration	107
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (Part 1): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	105
Correction: Multi-modal proteomic characterization of lysosomal function and proteostasis in progranulin-deficient neurons	101
Astrocytes of the optic nerve exhibit a region-specific and temporally distinct response to elevated intraocular pressure	98
Melatonin: a ferroptosis inhibitor with potential therapeutic efficacy for the post-COVID-19 trajectory of accelerated brain aging and neurodegeneration	95
A novel AAV Vector for gene therapy of RPE-related retinal degenerative diseases via intravitreal delivery	92
An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders	86

CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals	83
Microglial CD2AP deficiency exerts protection in an Alzheimer’s disease model of amyloidosis	82
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy	81
Pharmacological rescue of cognitive function in a mouse model of chemobrain	81
The TGFβ/Notch axis facilitates Müller cell-to-epithelial transition to ultimately form a chronic glial scar	80
Glial interference: impact of type I interferon in neurodegenerative diseases	79
LRP1: a novel receptor for the transmission of pathological α-Synuclein	79
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	74
Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases	74
Specific detection of tau seeding activity in Alzheimer’s disease using rationally designed biosensor cells	73
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023	65
TREM2 and microglia exosomes: a potential highway for pathological tau	62
Optimizing detection of Alzheimer’s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO	61
Unraveling the complex role of MAPT-containing H1 and H2 haplotypes in neurodegenerative diseases	61
The gut microbiome regulates astrocyte reaction to Aβ amyloidosis through microglial dependent and independent mechanisms	59
TDP-43 pathology is associated with increased tau burdens and seeding	59
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications	59
Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy	57
Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology	57
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	57
Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer’s disease: an updated overview of nonpharmacological therapies	56
Mitochondrial CISD1/Cisd accumulation blocks mitophagy and genetic or pharmacological inhibition rescues neurodegenerative phenotypes in Pink1/parkin models	55
Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium	54
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	53
Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination	52
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	52
A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer’s disease patients from controls	48
Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson’s disease	48
A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy	48
A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques	47
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	46
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	46
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	46
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease	45
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	45
Fluid biomarkers for amyotrophic lateral sclerosis: a review	45
Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice	45
The informed road map to prevention of Alzheimer Disease: A call to arms	44
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	43
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	43
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays	42
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	42
In memoriam of Huaxi Xu, PhD, 1964–2022	41
VCP suppresses proteopathic seeding in neurons	41
Preclinical studies and transcriptome analysis in a model of Parkinson’s disease with dopaminergic ZNF746 expression	40
α-Synuclein serine129 phosphorylation – the physiology of pathology	40
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	39
Correction: Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	38
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	37
Correction to: New approaches to symptomatic treatments for Alzheimer’s disease	37

Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA	36
Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come	35
Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy	35
Common mouse models of tauopathy reflect early but not late human disease	34
TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains	34
Rejuvenating aged microglia by p16ink4a-siRNA-loaded nanoparticles increases amyloid-β clearance in animal models of Alzheimer’s disease	33
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	33
Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease	32
Comparing anti-tau antibodies under clinical trials and their epitopes on tau pathologies	32
One immune cell to bind them all: platelet contribution to neurodegenerative disease	32
Are oligodendrocytes the missing link in Alzheimer’s disease and related dementia research?	32
SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease	31
TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation	31
Neuroprotection by WldS depends on retinal ganglion cell type and age in glaucoma	31
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	31
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications	30
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	30
RETRACTED ARTICLE: Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4	30
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset	29
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	29
Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	28
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels	28
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy	27
Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD	27
Mechanisms of astrocyte aging in reactivity and disease	27
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	27
The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease	27